Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia

Blood Cancer J. 2016 Nov 4;6(11):e490. doi: 10.1038/bcj.2016.96.

Authors

W Wang¹, Z Chen¹, Z Hu¹, C C Yin¹, S Li¹, S Bai¹, C E Bueso-Ramos¹, L J Medeiros¹, S Hu¹

Affiliation

¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Chromosomes, Human, Pair 8 / drug effects
Female
Humans
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Survival Analysis
Trisomy
Young Adult

Substances

Protein Kinase Inhibitors
Protein-Tyrosine Kinases

Supplementary concepts

Chromosome 8, trisomy